CARLSBAD, Calif., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (Nasdaq:SGNL) (Signal), a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced the extension of its exclusive laboratory services agreements with the University of Arkansas for Medical Sciences (UAMS). Under the agreement, the Company will be the exclusive provider of gene array clinical genetic testing services for UAMS until September 19, 2017. The agreements serve to renew and extend the current exclusive laboratory services agreements dated March 11, 2011.
Sam Riccitelli, Signal President and CEO, commented, "UAMS is a leading research center for the treatment of multiple myeloma and we are excited to continue our longstanding laboratory services arrangement for an additional three years. We believe this is further validation of the quality of our testing services and clear evidence of the need to provide physicians with the means to make better-informed treatment decisions in order to improve patient survival rate and quality of life."
About Signal Genetics, Inc.
Signal Genetics, Inc., headquartered in Carlsbad, California, is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. The Company's mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions. Signal was founded in January 2010 and became the exclusive licensee in its licensed field to the renowned research on multiple myeloma performed at UAMS, in April 2010.
CONTACT: INVESTOR CONTACT: The Ruth Group David Burke Tel: 646-536-7009 email@example.comSource:Signal Genetics, Inc.